Part 2 of our Strategies to Speed Clinical Trials Series The path from therapeutic discovery to regulatory approval remains long, with significant time devoted to clinical testing. When investing up to 15 years or more in a potential therapeutic, with much of that time dedicated to clinical trials1, any opportunity to save time during clinical phases can […]
View Blog
Part 29 of our Bridging the Gap Series (Summary of the webinar session held in April 2026) For all the scientific progress in cell and gene therapy, one of the field’s biggest challenges remains the same: how to turn innovation into sustainable patient access. That question is especially important in regions where healthcare systems are growing quickly, […]
View Blog
Part 1 of our Strategies to Speed Clinical Trials Series In the ever-competitive drug development landscape, time is a precious and limited resource. During often-complex clinical trials, every delay can have a real-world impact on patients, healthcare systems, and the bottom line. In fact, one recent review determined that reducing clinical development time from 10 months to […]
View Blog
Part 28 of our Bridging the Gap Series (Summary of the webinar session held in March 2026) For all the progress in cell and gene therapy, getting these treatments to patients remains one of the field’s greatest challenges. Today, only a fraction of eligible patients are able to access these therapies—often due not to science, but to […]
View Blog
Part 27 of our Bridging the Gap Series (Summary of the webinar session held in February 2026) CAR-T therapy has already demonstrated what’s possible in certain blood cancers. However, solid tumors are proving much harder to treat. This challenge was the focus of Azenta’s recent Bridging the Gap webinar. Moderated by Olga Bukatova, Associate Director of Business […]
View Blog
Part 26 of our Bridging the Gap Series (Summary of the webinar session held in January 2026) Cell and gene therapy is changing what’s possible for patients, particularly through CAR-T therapies for certain cancers. But access isn’t equal. Who receive treatment—and when—often comes down to geography, manufacturing capacity, cost, and infrastructure. Recently, leaders from Canada’s cell therapy […]
View Blog
Part 25 of our Bridging the Gap Series (Summary of the webinar session held in December 2025) Editor’s note: Since this webinar, Waskyra has also received approval from the U.S. Food and Drug Administration (FDA), expanding access beyond Europe. One of the hardest challenges in cell & gene therapy (CGT) is determining how programs for ultra-rare diseases […]
View Blog
Part 24 of our Bridging the Gap Series (Summary of the webinar session held in November 2025) Access to life-saving cell and gene therapies depends not only on scientific breakthroughs but also on the systems that bring those breakthroughs to patients. Regulations, infrastructure, and collaboration across borders determine whether a therapy moves from the lab to the […]
View Blog
Part 23 of our Bridging the Gap Series (Summary of the webinar session held in October 2025) The last decade has seen a revolution in the way cell and gene therapies are developed, delivered, and accessed. What began as pioneering work in bone marrow transplantation has evolved into a global ecosystem advancing engineered cell therapies that offer […]
View Blog
Part 22 of our Bridging the Gap Series (Summary of the webinar session held in September 2025) Access to advanced therapies is often framed as a challenge of resources and infrastructure. But in Europe, a bold new model is reshaping how patients receive life-saving CAR T-cell therapy. Instead of relying solely on commercial manufacturing and centralized approval […]
View Blog